On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India. With this agreement, Novavax increased its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021.

NVX-CoV2373 is a stable, prefusion protein made using Novavaxﾒ recombinant protein nanoparticle technology and includes Novavaxﾒ proprietary Matrix-Mﾙ adjuvant.